<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02895022</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0271</org_study_id>
    <secondary_id>2016-000224-26</secondary_id>
    <nct_id>NCT02895022</nct_id>
  </id_info>
  <brief_title>EpiConCES - Epidural Lidocaine for Conversion to CaEsarean Section</brief_title>
  <acronym>EpiConCES</acronym>
  <official_title>Determination of ED95 of 2% Lidocaine With Epinephrine for Converting Analgesia Epidural Anesthesia in Surgical Epidural in the Labor Current Cesarean</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      The need to resort to a midwifery course work in cesarean is a common practice. Epidural
      analgesia for labor analgesia is practiced in 90% of women in obstetric work, as when the
      cesarean decision is taken course work in practice and the recommendations are to use the
      epidural catheter in place to convert the epidural analgesia in epidural anesthesia by
      re-injecting a local anesthetic on the catheter. General anesthesia is reserved only cases of
      extreme urgency and cons-indications for regional anesthesia as a purveyor of high maternal
      morbidity and mortality.

      The initial assumption is that the 2% lidocaine with epinephrine is the optimal and
      recommended local anesthetic solution.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a real variability in the volume administered by practitioners repository fault.

      The main objective is to determine the ED95 dose of 2% lidocaine with epinephrine injected
      into the epidural catheter for which it does not arise from failure to surgical anesthesia
      for cesarean during labor.

      The secondary objectives are to determine the failure risk factors, the hemodynamic
      consequences related to the volume administered and evaluate maternal satisfaction.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success or failure of lidocaine 2% with epinephrine dose administered</measure>
    <time_frame>at day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study tolerance of epidural anesthesia for caesarean section</measure>
    <time_frame>at day 1</time_frame>
    <description>Study tolerance - including hemodynamics - of epidural anesthesia for caesarean section depending on the dose of 2% lidocaine with epinephrine administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maternal pain (Visual Analog Scale)</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maternal satisfaction</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nausea and vomiting intraoperatively</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure (PAM, PAS (mmHg))</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fluid replacement (ml)</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypotension</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>necessary to use vasopressors</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar score</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fetal arterial and venous cord pH</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intravenous sedation for inadequate anesthesia</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pregnant Women&gt;37SA</condition>
  <arm_group>
    <arm_group_label>Lidocaine 2% adrénalinée</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The main objective is to determine the ED95 dose of 2% lidocaine with epinephrine injected into the epidural catheter for which it does not arise from failure to surgical anesthesia for cesarean during labor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine 2% adrénalinée</intervention_name>
    <arm_group_label>Lidocaine 2% adrénalinée</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Epidural catheter</intervention_name>
    <arm_group_label>Lidocaine 2% adrénalinée</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Caesarean section</intervention_name>
    <arm_group_label>Lidocaine 2% adrénalinée</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant &gt; 37SA

          -  Between 150 and 190cm

          -  IMC between 20 and 40

          -  Single pregnancy

          -  Elective cesarean indication during obstetric labor

        Exclusion Criteria:

          -  Presentation of siege

          -  Extreme and semi emergency caesarean indication
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martine BONNIN</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>04 73 75 11 95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>04 73 75 11 95</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Martine BONNIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brigitte STORME</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurélie FOURNET-FAYARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agnès BARRIERE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian CHARTIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppe ROSANO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Laure LAFAYE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lise VERNIS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie FAYON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis GALLOT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2016</study_first_submitted>
  <study_first_submitted_qc>September 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2016</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

